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Abstract
Background: Resveratrol (3, 49, 5 tri-hydroxystilbene), a naturally occurring polyphenol, exhibits anti-inflammatory,
antioxidant, cardioprotective and antitumor activities. We have recently shown that resveratrol can enhance the apoptosis-
inducing potential of TRAIL in prostate cancer cells through multiple mechanisms in vitro. Therefore, the present study was
designed to validate whether resveratrol can enhance the apoptosis-inducing potential of TRAIL in a xenograft model of
prostate cancer.
Methodology/Principal Findings: Resveratrol and TRAIL alone inhibited growth of PC-3 xenografts in nude mice by
inhibiting tumor cell proliferation (PCNA and Ki67 staining) and inducing apoptosis (TUNEL staining). The combination of
resveratrol and TRAIL was more effective in inhibiting tumor growth than single agent alone. In xenografted tumors,
resveratrol upregulated the expressions of TRAIL-R1/DR4, TRAIL-R2/DR5, Bax and p27
/K IP1, and inhibited the expression of
Bcl-2 and cyclin D1. Treatment of mice with resveratrol and TRAIL alone inhibited angiogenesis (as demonstrated by
reduced number of blood vessels, and VEGF and VEGFR2 positive cells) and markers of metastasis (MMP-2 and MMP-9). The
combination of resveratrol with TRAIL further inhibited number of blood vessels in tumors, and circulating endothelial
growth factor receptor 2-positive endothelial cells than single agent alone. Furthermore, resveratrol inhibited the
cytoplasmic phosphorylation of FKHRL1 resulting in its enhanced activation as demonstrated by increased DNA binding
activity.
Conclusions/Significance: These data suggest that resveratrol can enhance the apoptosis-inducing potential of TRAIL by
activating FKHRL1 and its target genes. The ability of resveratrol to inhibit tumor growth, metastasis and angiogenesis, and
enhance the therapeutic potential of TRAIL suggests that resveratrol alone or in combination with TRAIL can be used for the
management of prostate cancer.
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Introduction
Resveratrol (3, 4’, 5 tri-hydroxystilbene), a naturally occurring
polyphenol, exhibits pleiotropic health benefits including anti-
inflammatory, antioxidant, cardioprotective and antitumor activ-
ities [1,2,3,4]. Currently, numerous preclinical findings suggest
resveratrol as a promising agent for cancer prevention and/or
treatment. As a potential anti-cancer agent, resveratrol has been
shown to inhibit or retard the growth of various cancer cells in vitro
and implanted tumors in vivo [5,6,7,8,9]. Resveratrol has been
shown to inhibit the activation of JAK2-STAT3, Src-STAT3,
AKT and IKK-NFkB pathways and to induce apoptosis in several
cancer cell lines [10,11,12,13]. We have recently demonstrated
that resveratrol downregulated the expression of Bcl-2, Bcl-XL and
survivin and upregulated the expression of Bax, Bak, PUMA,
Noxa, and Bim and death receptors (TRAIL-R1/DR4 and
TRAIL-R2/DR5) [1,14,15]. Furthermore, Treatment of prostate
cancer cells with resveratrol resulted in generation of reactive
oxygen species (ROS), translocation of Bax to mitochondria and
subsequent drop in mitochondrial membrane potential, release of
mitochondrial proteins (cytochrome c, Smac/DIABLO, and AIF)
to cytosol, activation of effector caspase-3 and caspase-9, and
induction of apoptosis [1,14,15]. Resveratrol-induced ROS
production, caspase-3 activity and apoptosis were inhibited by
N-acetylcysteine, suggesting the ROS production, at least in part,
plays a role in mediating anticancer activities of resveratrol
[1,14,15]. Resveratrol enhanced the apoptosis-inducing potential
of TRAIL in PC-3 cells and sensitized TRAIL-resistant prostate
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15627cancer LNCaP cells in vitro [1,14,15]. Overall, these data suggest
that resveratrol can regulate multiple signaling pathways and
possesses several therapeutic benefits.
PI3K signaling plays a pivotal role in intracellular signal
transduction pathways involved in cellular transformation, cell
growth, and tumorigenesis [16,17]. Inactivation of AKT results in
dephosphorylation and activation of FOXO transcription factors,
reported to mediate cell cycle arrest, DNA repair, and apoptosis
[18,19]. These transcription factors, belong to the ‘O’ subgroup of
winged-helix/forkhead transcription-factor family, consist princi-
pally of four members FOXO1, FOXO3a, FOXO4, and FOXO6
[20]. FOXO proteins are evolutionarily conserved transcription
factors implicated in several fundamental cellular processes,
functioning as end-point for transcriptional programs involved in
apoptosis, stress response and longevity [21,22]. Since abrogation
of FOXO function is frequently observed in human cancer, the
reactivation of FOXO proteins will be an attractive strategy for
cancer therapy and prevention. The FOXO proteins integrate
regulatory inputs from a variety of upstream signaling pathways,
most importantly in response to growth factor and stress signaling
[23]. Recently, FOXO factors have been established as tumor
suppressors, promoting the transcription of pro-apoptotic mole-
cules like FasL and Bim when the PI3K/AKT pathway is
downregulated due to nutrient or serum starvation and cellular
stress [24,25]. Triple knockout mouse models proved the tumor
suppressor properties of FOXOs, as mice simultaneously lacking
the principal members of the mammalian FOXO subfamily,
FOXO1, FOXO3a and FOXO4, are prone to develop heman-
giomas and lymphoproliferative diseases [26]. Conversely, the
individual or paired inactivation of FOXO1, FOXO3a or
FOXO4 resulted in a less severe phenotype, supporting the idea
of functional redundancy of these FOXO factors [26]. Further-
more, forced expression of FOXO has been shown to inhibit
tumorigenesis in xenograft models in nude mice [27,28].
Therefore, reactivation of FOXO based on its tumor suppressor
properties is considered as a very attractive anti-cancer strategy.
Since FOXO proteins were reported to be critical mediators of
apoptosis induced by anticancer drugs, we postulated that FOXO
expression or transcriptional activity could be important event in
mediating the effects of resveratrol.
TNF-related apoptosis-inducing ligand (TRAIL) has been
shown to TRAIL-R1/DR4 and TRAIL-R2/DR5 [29]. We and
others have shown that TRAIL can induce apoptosis in various
cancer cell types [29,30,31,32,33]. Based on preclinical data, it
appears that TRAIL has great promise as a selective anticancer
agent [31,32]. Resveratrol has been shown to enhance the
therapeutic potential of TRAIL in vitro [14,34]. The interactions
of resveratrol and TRAIL were blocked by either dominant
negative FADD or caspase-8 siRNA [14,15]. The combination
of resveratrol and TRAIL enhanced the mitochondrial dysfunc-
tions during apoptosis. Resveratrol treatment can activate the
extrinsic TRAIL-receptor-mediated death pathway, thereby
increasing sensitivity to TRAIL in prostate cancer cells.
However, the molecular mechanisms by which resveratrol can
enhance the therapeutic potential of TRAIL in vivo has not been
examined.
The purpose of our study was to investigate the molecular
mechanisms by which resveratrol enhances the therapeutic
potential of TRAIL in prostate cancer xenografts in nude mice.
Our results indicated that resveratrol inhibited PC-3 xenograft
growth and markers of metastasis, and angiogenesis through
activation of FOXO transcription factors. Thus, our data suggest
that resveratrol can be used alone or in combination with TRAIL
for the management of of prostate cancer.
Results
Resveratrol enhances antitumor tumor activity of TRAIL
in PC-3 xenografts in vivo
We have recently shown that resveratrol can enhance the
apoptosis inducing potential of TRAIL in vitro. Therefore, in the
present study, we examined whether resveratrol can enhance the
antitumor activity of TRAIL in vivo. PC-3 cells were xenografted in
Balb c nude mice. After tumor formation, these mice were treated
with resveratrol, TRAIL, or resveratrol plus TRAIL for 6 weeks
and the effects of these agents on tumor growth were examined.
Resveratrol and TRAIL alone inhibited growth of PC-3
xenografts (Fig. 1). By comparison, the combination of resveratrol
and TRAIL was more effective in inhibiting tumor growth than
single agent alone.
These data suggest that resveratrol can enhance the antitumor
activity of TRAIL in prostate cancer.
Regulation of tumor cell proliferation and apoptosis by
resveratrol and/or TRAIL in PC-3 xenografts
Tumor cell proliferation and apoptosis can regulate the size of
tumor at any given time. Therefore, we performed immunohis-
tochemistry in tumor tissues to measure the expression of Ki67
and PCNA, and TUNEL assay to measure apoptosis (Fig. 2A).
Tumor cell proliferation was measured by counting Ki67 and
PCNA positive cells, and apoptosis was measured by counting
TUNEL positive cells (Fig. 2B–D). Treatment of mice with
resveratrol and TRAIL alone resulted in inhibition of tumor cell
proliferation, and induction in apoptosis. The combination of
resveratrol and TRAIL was more effective in inhibiting tumor cell
proliferation and inducing apoptosis than single agent alone.
These data suggest that resveratrol, although effective alone, can
enhance the antitumor activity of TRAIL in prostate cancer.
In vivo regulation of death receptor TRAIL-R1/DR4 and
TRAIL-R2/DR5 by resveratrol and/or TRAIL
Since resveratrol enhances the therapeutic potential of TRAIL
by inducing apoptosis in vivo, we sought to examine the molecular
mechanisms by which resveratrol enhances the antitumor activity
of TRAIL in PC-3 xenografts. We next examined the effects of
resveratrol and/or TRAIL on the expression of death receptors
(TRAIL-R1/DR4 and TRAIL-R2/DR5) by immunohistochem-
istry in tumor tissues derived from in vivo experiment (Fig. 3A, left
Figure 1. Resveratrol enhances apoptosis-inducing potential of
TRAIL in PC-3 xenografts. (A), PC-3 cells were injected into the right
flanks of Balb c nude mice. After tumor formation (about 100 mm
3),
mice were treated with saline, resveratrol (30 mg/kg, three days per
week), TRAIL (15 mg/kg, four times during first three weeks) or
resveratrol plus TRAIL. Tumor volume was measured weekly. Data
represent mean 6 SE. *, # and $ are significantly different from control,
P,0.05).
doi:10.1371/journal.pone.0015627.g001
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the expressions of DR4 and DR5. TRAIL slightly induced the
expression of DR4 and DR5. On the other hand, treatment of
mice with a combination of resveratrol plus TRAIL significantly
showed enhanced expressions of DR4 and DR5 proteins than that
of mice treated with resveratrol alone or TRAIL alone.
We confirmed the immunohistochemistry data by examining
the expression of these proteins by the Western blot analysis
(Fig. 3B). Treatment of mice with Resveratrol and TRAIL alone
resulted in upregulation of death receptors DR4 and DR5. By
comparison, resveratrol plus TRAIL treatments had more effects
on the induction of DR4 and DR5 compared to single agent
alone. These data are in agreement with immunohistochemistry
data where the proapoptotic DR4 and DR5 proteins were
upregulated.
We next confirmed the immunohistochemistry and western blot
data by examining the expressions of DRs by ELISA (Fig. 3C,
right panel). Treatment of mice with resveratrol and TRAIL alone
upregulated the expression of death receptors (DR4 and DR5). By
comparison, the combination of resveratrol plus TRAIL induced
more DR4 and DR5 expressions than single agent alone. These
data are in agreement with immunohistochemistry and western
blot data where the proapoptotic DR4 and DR5 proteins were
upregulated by resveratrol and TRAIL. Up-regulation of DRs
may enhance the apoptosis-inducing potential of TRAIL.
In vivo regulation of Bcl-2 family members and cell cycle
regulatory proteins by resveratrol and/or TRAIL
Since Bcl-2 family members play a major role in apoptosis, we
sought to examine the expression of Bax and Bcl-2 in tumor tissues
derived from resveratrol and/or TRAIL-treated mice (Fig. 4A, left
panel). Treatment of mice with resveratrol and TRAIL alone
resulted in upregulation of Bax, and inhibition of Bcl-2 expression.
By comparison, the combination of resveratrol plus TRAIL was
more effective in upregulating Bax and inhibiting Bcl-2. We next
confirmed the Western blot data by examining the expressions of
these proteins by immunohistochemistry (Fig. 4A, middle and
right panels). Treatment of mice with resveratrol upregulated the
expression of Bax and inhibited the expression of Bcl-2. By
comparison, treatment of mice with a combination of resveratrol
plus TRAIL had more effects on the upregulation of Bax and
inhibition of Bcl-2 than single agent alone.
Figure 2. Effects of resveratrol and/or TRAIL on tumor cell proliferation and apoptosis. (A), Immunohistochemistry was performed in
tumor tissues derived from control, resveratrol and/or TRAIL treated mice on week 6 to measure cell proliferation by Ki67 and PCNA staining and
apoptosis by TUNEL assay. (B, C and D), Quantification of Ki67, PCNA and TUNEL positive tumor cells. Tumor slides of different treatment groups were
visualized under microscope, and Ki67, PCNA and TUNEL positive cells were quantified. Data represent mean 6 SE. * and ** are significantly different
from their respective controls, P,0.05).
doi:10.1371/journal.pone.0015627.g002
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the expressions of TRAIL-R1/DR4 and TRAIL-R2/DR5 in tumor tissues derived from control and treated mice on week 6. Quantification of DR4 and DR5
positive cells are also shown on right panel. (B), Expressions of TRAIL-R1/DR4, TRAIL-R2/DR5 and b-actin in tumor tissues derived on week 6. Western
blot analysis was performed to measure the expression of DRs (left panel). Quantification of DR4 and DR5 positive tumor cells (right panel). (C), Mea-
surement of DR4 and DR5 by ELISA. Proteins extracts were prepared and the expressions of DRs were measured as per manufacturer’s instructions.
doi:10.1371/journal.pone.0015627.g003
Figure 4. Effects of resveratrol and/or TRAIL on Bcl-2 family members and cell cycle regulatory proteins. (A), Western blot analysis was
performed to measure the expressions of Bax and Bcl-2 in tumor tissues derived from control, resveratrol and/or TRAIL treated mice on week 6 (left
panel). Immunohistochemistry was performed to measure the expressions of Bax and Bcl-2 in tumor tissues derived from control and drug treated
mice on week 6 (middle panel). Quantification of Bax and Bcl-2 positive cells in tumor cells (right panel). (B), Western blot analysis was performed to
measure the expressions of p27
/KIP1 and cyclin D1 in tumor tissues derived from control and drug treated mice on week 6 (left panel).
Immunohistochemistry was performed to measure the expressions of p27
/KIP1 and cyclin D1 in tumor tissues derived from control and drug treated
mice on week 6 (middle panel). Quantification of p27
/KIP1 and cyclin D1 positive cells in tumor tissues (right panel).
doi:10.1371/journal.pone.0015627.g004
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the expression of p27
/KIP1 and cyclin D1 in tumor tissues by
Western blotting and immunohistochemistry (Fig. 4B). Treatment
of mice with resveratrol resulted in the induction of cell cycle
inhibitor p27
/KIP1 and inhibition of cyclin D1 expression (Fig. 4B).
By comparison, TRAIL had no significant effect on p27
expression, but slightly inhibited the expression of cyclin D1
compared to control group. However, the combination of
resveratrol and TRAIL showed upregulation of p27, and
inhibition of cyclin D1 compared to single agent alone. We next
confirmed the Western blot data with immunohistochemistry data
by examining the expressions of these proteins (Fig. 4B, middle
and right panels). TRAIL has no significant effect on the
expression of p27 but slightly inhibited the expression of cyclin
D1. By comparison, resveratrol induced the expressions of p27,
and inhibited the expression of cyclin D1. These data suggest that
resveratrol can regulate cell cycle by up-regulating the expression
of p27 and inhibiting the expression of cyclin D1.
In vivo regulation of MMP-2 and MMP-9 expression by
resveratrol and/or TRAIL
Elevated expressions of matrix metalloproteinases (MMPs) are
associated with increased metastatic potential in many tumor cells
[35,36,37]. We therefore sought to examine the effects of
resveratrol on MMP-2 and MMP-9 expressions in tumor tissues
derived from xenografted nude mice by immunohistochemistry
and Western blot analysis. Treatment of xenogrfated mice with
resveratrol resulted in inhibition of MMP-2 and MMP-9
expressions than those of control or TRAIL treated group
(Fig. 5A and B). The combination of resveratrol and TRAIL
was more effective in inhibiting MMP-2 and MMP-9 expressions
than single agent alone. We next confirmed the immunohisto-
chemistry data by examining the expressions of these proteins by
Western blot analysis (Fig. 5C). TRAIL has no significant effect on
the expressions of MMP-2 and MMP-9. By comparison,
resveratrol or resveratrol plus TRAIL inhibited the expressions
of MMP-2 and MMP-9. These data suggest that resveratrol and/
or TRAIL may inhibit prostate cancer metastasis by inhibiting
MMP-2 and MMP-9.
In vivo regulation of angiogenesis by resveratrol and/or
TRAIL
Whether regression in tumor growth by resveratrol and/or
TRAIL was due to inhibition of angiogenesis, we analyzed the
markers of angiogenesis by immunohistochemistry in tumor tissues
derived from control and treated mice (Fig. 6). We first examined
the effects of resveratrol and/or TRAIL treatment on number of
blood vessels in tumor tissues by utilizing three different
approaches (Fig. 6A). Blood vessels were examined by staining
the tumor tissues by H&E, anti-CD31 antibody, and anti-vWF
antibody. Treatment of mice with resveratrol or TRAIL caused an
inhibition in number of blood vessels. By comparison, the
treatment of mice with a combination of resveratrol plus TRAIL
further inhibited the number of blood vessels.
We next examined the expression of VEGF by immunohisto-
chemistry and Western blot analysis (Fig 6). Examination of tumor
tissues by immunohistochemistry showed that control mice had
increased VEGF-positive endothelial cells compared to resveratrol
Figure 5. Effects of resveratrol and/or TRAIL on markers of metastasis. (A), Immunohistochemistry was performed to measure the
expressions of MMP-2 and MMP-9 in tumor tissues derived from control, resveratrol and/or TRAILtreated mice on week 6. (B), Quantification of MMP-2
and MMP-9 positive cells in tumor tissues. (C), Expressions of MMP-2, MMP-9 and b-actin in tumor tissues were measured on week 6 by the Western
blot analysis.
doi:10.1371/journal.pone.0015627.g005
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combination of resveratrol plus TRAIL showed significantly less
VEGF staining than single agent alone. We next confirmed the
immunohistochemistry data of VEGF expression by examining
the protein levels by Western blot analysis (Fig. 6B, lower panel).
Treatment of mice with resveratrol and TRAIL alone inhibited
VEGF expression. By comparison, resveratrol plus TRAIL
inhibited the expression of VEGF.
We have demonstrated that numbers of circulating vascular
endothelial growth factor receptor 2 (VEGF-R2)-positive endo-
thelial cells correlate directly with increase in tumor angiogenesis
and can serve as in vivo indicators of tumor angiogenesis [31,38].
As expected, control mice had increased circulating VEGF-R2-
positive endothelial cells compared to resveratrol treated mice
(Fig. 6C). Resveratrol plus TRAIL-treated group demonstrated
significantly less VEGFR2-positive cells than that of resveratrol or
TRAIL treated group. These data strongly demonstrate that
resveratrol can inhibit tumor growth by inhibiting angiogenesis,
and may also promote antitumor activity of TRAIL in vivo.
In vivo regulation of transcription factor FKHRL1
AKT has been shown to phosphorylate FKHRL1, and the
inhibition of FKHRL1 phosphorylation causes its nuclear
translocation, enhanced DNA binding and transcriptional activity
[39]. We next examined whether antitumor activities of resveratrol
and/or TRAIL are exerted through activation of FKHRL1
Figure 6. Effects of resveratrol and/or TRAIL on markers of angiogenesis. (A), Left panel, tumor tissue sections derived from control,
resveratrol and/or TRAIL treated mice on week 6 were stained with H & E and the numbers of blood vessels were counted at 400 X magnification.
Each column represents the mean 6 SD. * or ** = significantly different from control, P,0.05. Middle panel, blood vessel quantification in tumors
derived on week 6. Tumor sections from control and drug treated mice were stained with anti-CD31 antibody, and the numbers of CD31-positive
blood vessels were counted. The results are shown as the mean 6 SD. * or ** = significantly different from control, P,0.05. Right panel, tumor
sections from control and drug treated mice obtained on week 6 were stained with anti-von Willebrand Factor (vWF) antibody to evaluate blood
vessels. The results are shown as the mean 6 SD. * or ** = significantly different from control, P,0.05. (B), Left panel, immunohistochemistry was
performed to measure the expression of VEGF in tumor tissues derived from control and drug treated mice on week 6. Right panel, quantification of
VEGF positive cells in tumor tissues. Right panel, quantification of VEGF positive cells. The results are shown as the mean 6 SD. * or ** = significantly
different from control, P,0.05. Bottom panel, expressions of VEGF and b-actin in tumor tissues derived on week 6 were measured by the Western
blot analysis. (C), VEGF receptor 2 (VEGF-R2)-positive circulating endothelial cells in mice on week 6. The blood cells from peripheral blood attached
to the slide were stained with anti-VEGF-R2 antibody, and the number of VEGF-R2 positive cells was counted under a microscope. The results are
shown as the mean 6 SD. * or ** = significantly different from control, P,0.05.
doi:10.1371/journal.pone.0015627.g006
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FKHRL1; however, resveratrol was more effective than TRAIL.
The combination of resveratrol and TRAIL had more effect in
inhibiting phosphorylation of FKHRL1 than single agent alone.
We next examined the phosphorylation of FKHRL1 in tumor
tissues by immunohistochemistry (Fig. 7B and C). Resveratrol and
TRAIL inhibited the cytoplasmic levels of phosphorylated
FKHRL1 as shown in Fig. 7B and quantified in Fig. 7C. The
combination of resveratrol plus TRAIL had more effect in
inhibiting cytoplamic levels of phosphorylated FKHRL1 than
single agent alone. These data suggest that resveratrol and TRAIL
can inhibit the phosphorylation of FKHRL1, which may results in
its nuclear translocation and activation.
We next examined the FKHRL1-DNA binding activity by
gelshift assay (Fig. 7D). Nuclear extracts were prepared from
tumor tissues derived from resveratrol and/or TRAIL treated
mice. Gelshift data revealed that TRAIL and resveratrol enhanced
FKHRL1-DNA binding activities. The combination of resveratrol
and TRAIL had significantly more FKHRL1-DNA binding
activity than single agent alone. Overall, these data suggest that
resveratrol and TRAIL can inhibit the phosphorylation of
FKHRL1 leading to its enhanced nuclear translocation and
DNA binding activities.
Discussion
We have recently shown that resveratrol induces apoptosis in
TRAIL-sensitive PC-3 cells, and sensitizes TRAIL-resistant
LNCaP cells in vitro through activation of multiple signaling
pathways [14,15]. Resveratrol-induced apoptosis engages mito-
chondria, as was shown by a drop in mitochondrial membrane
potential and activation of caspase-3 and caspase-9 in both
prostate cancer PC-3 and LNCaP cells [14,15]. Resveratrol
induced expression of proapoptotic proteins (Bax, Bak, PUMA,
Noxa and Bim), death receptors (TRAIL-R1/DR4 and TRAIL-
R2/DR5), and inhibited expression of anti-apoptotic proteins (Bcl-
2 and Bcl-XL) and IAPs (XIAP and survivin). In our recent study,
resveratrol regulated the expression of TRAIL, DR4, DR5, Bim,
p27
/KIP1 and cyclin D1 through FOXO transcription factors in
vitro, and inhibition of FKHRL1, FKHR and AFX by RNAi
blocked these affects of resveratrol [40]. In the present study, we
have validated our in vitro findings and demonstrated that
Figure 7. Activation of transcription factor FKHRL1 by resveratrol. (A), Inhibition of FKHRL1 phosphorylation by resveratrol. Western blot
analysis was performed to measure the expression of phospho-FKHRL1 in tumor tissues derived from control and/or drug treated mice on week 6. (B),
Immunohistochemical examination of phospho-FKHRL1. Immunohistochemistry was performed to measure the expression of phospho-FKHRL1 in
tumor tissues derived from control, resveratrol and/or TRAIL treated mice on week 6. (C), Quantification of FKHRL-positive cells in tumor tissues. (D),
FKHRL1-DNA binding activity. Nuclear extracts were prepared from tumor tissues derived from control and drug-treated mice. Gelshift assay was
performed to measure the FKHRL1-DNA binding activity as described in Materials and Methods.
doi:10.1371/journal.pone.0015627.g007
Resveratrol Activates FOXO in Prostate Cancer
PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e15627resveratrol and TRAIL alone inhibited the growth of PC-3
xenografts, metastasis and angiogenesis through activation of
FOXO transcription factors. Interestingly, the combination of
resveratrol and TRAIL had greater effect on the inhibition of
tumor growth, metastasis and angiogenesis than either agent
alone.
In vitro resveratrol downregulated the expressions of Bcl-2 and
Bcl-XL and upregulated the expressions of p53, Bax, Bak, PUMA,
Noxa, and Bim at mRNA and protein levels in prostate cancer
cells [41]. We have also demonstrated that resveratrol upregulated
the expression, phosphorylation, and acetylation of p53 in
androgen-dependent LNCaP cells [41]. The ability of resveratrol
to regulate gene transcription was also evident as it caused
acetylation of histone H3 and H4 in LNCaP cells [41].
Furthermore, treatment of LNCaP cells with resveratrol resulted
in translocation of Bax and p53 to mitochondria, production of
reactive oxygen species, drop in mitochondrial membrane
potential, release of mitochondrial proteins (cytochrome c,
Smac/DIABLO and Omi/HtrA2), and activation of caspase-3
leading to apoptosis [41]. Furthermore, deletion of Bax and Bak
genes completely inhibited resveratrol-induced cytochrome c and
Smac/DIABLO release in mouse embryonic fibroblasts [42]. In
the present study, treatment of xenografted mice with resveratrol
resulted in downregulation of Bcl-2 and up-regulation of Bax. The
combination of resveratrol plus TRAIL was more effective in
regulating Bcl-2 family members than single agent alone. Our
previously published in vitro data are in agreement with current in
vivo studies which demonstrate that resveratrol can engage cell-
intrinsic pathway of apoptosis by regulating the expression of Bcl-2
family of proteins.
FOXO transcription factors are tumor suppressors that are
inactivated in the majority of human cancers, owing to the
overactivation of the PI3K/AKT pathway [43]. FOXO proteins
can regulate a variety of genes that influence cell proliferation,
survival, metabolism and response to stress [19,20,44]. FOXO
transcription factors are regulated by synthesis, acetylation,
phosphorylation and ubiquitination at three different levels:
subcellular localization, stability and transcriptional activity
[19,20,44]. Upon activation of PI3K/AKT signaling, FOXOs
undergo AKT-mediated phosphorylation, which promotes bind-
ing to 14-3-3, nuclear export through CRM1 and cytoplasmic
sequestration. Under stress conditions or in the absence of growth
or survival factors, when the PI3K/AKT pathway is inhibited,
FOXO proteins translocate to the cell nucleus, where their
transcriptional functions can be executed [45]. A second
regulatory layer is FOXO acetylation by p300, Cbp (CREB-
binding protein) and Pcaf (p300/CBP-associated factors) in
response to oxidative stress or DNA binding [46,47,48], followed
by deacetylation by class I and II histone deacetylases [48,49,50],
including Sirt1, the NAD
+-dependent deacetylase encoded by the
ortholog of yeast longevity gene Sir2 [51]. We have recently
demonstrated that inhibition of PI3K/AKT pathway enhanced
FOXO-DNA binding and transcriptional activity [40,52]. Fur-
thermore, phosphorylation deficient mutant of FOXO enhanced
resveratrol-induced FOXO transcriptional activity and apoptosis.
Post-translational modification of FOXO proteins is an important
mechanism that regulates the ability of different transcription
factors to activate distinct gene sets, involved in cell cycle
inhibition [53], apoptosis [54], defense against oxidative stress
and DNA repair [55]. The enhanced DNA binding activity also
serves to limit the availability of FOXO proteins for phosphor-
ylation by AKT [46]. In the present study, we have shown that
resveratrol induced apoptosis in prostate cancer cells through
activation of FOXO transcription factors. Similarly in another
study, we have demonstrated that inhibition of FOXO transcrip-
tion factors by shRNA blocked resveratrol-induced upregulation of
Bim, TRAIL, DR4, DR5, p27
/Kip1 and apoptosis, and resveratrol-
induced inhibition of cyclin D1 in prostate cancer cells in vitro [40].
Our data suggest that resveratrol induces cell cycle arrest and
apoptosis through regulation of FOXO transcription factors in
prostate cancer cells.
The FOXO transcription factors have been shown to be
constitutively activated in various human malignancies, including
prostate cancer [39,56]. FOXOs are shown to contribute to
development and/or progression of malignancy by regulating the
expression of genes involved in cell growth, differentiation,
apoptosis, angiogenesis and metastasis [39,56]. We have recently
demonstrated that FOXO transcription factors and VEGF
neutralizing antibody enhance anti-angiogenic effects of resvera-
trol [57]. Prostate cancer cells have been reported to have
constitutive FOXO activity due to increased activity of the AKT
and ERK kinases. Activation of FOXO may inhibit cell growth,
proliferation and angiogenesis, and induce apoptosis by regulating
expression of genes such as FasL, Bim, cyclin D1, p27 and TRAIL
[39,40,56]. Thus, FOXO-mediated expression of genes, involved
in angiogenesis, invasion and metastasis may further contribute to
the progression of prostate cancer. Constitutive FOXO activity
has also been demonstrated in primary prostate cancer tissue
samples and suggested to have prognostic importance for a subset
of primary tumors. In the present study, resveratrol induced the
activation of FKHRL1 and its gene products in PC-3 xenografted
tumors. These findings suggest that FOXO may play a role in
human prostate cancer development, and/or progression, and
resveratrol can inhibit these processes through regulation of
FOXO-regulated gene products.
During malignant neoplastic progression the cells undergo
genetic and epigenetic cancer specific alterations that finally lead
to a loss of tissue homeostasis and restructuring of the
microenvironment. The invasion of cancer cells through connec-
tive tissue is a crucial prerequisite for metastasis formation. MMPs
are up-regulated in many tumors and have been implicated in
tumor progression and metastasis. MMPs are critical for
pericellular degradation of the extracellular matrix, thereby
promoting tumor cell invasion and dissemination. To grow
efficiently in vivo, tumor cells induce angiogenesis in both primary
solid tumors and metastatic foci. In the present study, treatment of
xenografted mice with resveratrol plus TRAIL significantly
inhibited tumor cell proliferation, metastasis and angiogenesis,
and induced apoptosis than single agent alone. Furthermore,
resveratrol inhibited the growth of PC-3 xenografts and enhanced
the apoptosis-inducing potential of TRAIL probably through
regulation of apoptosis, angiogenesis and metastasis.
TRAIL induces apoptosis in cancer cells which express TRAIL-
R1/DR4 and TRAIL-R2/DR5. We have shown that the
upregulation of death receptors by chemotherapeutic drugs,
irradiation and chemopreventive agents enhance or sensitize cancer
cells to TRAIL treatment [1,14,15,29,32,58,59,60,61,62,63]. Spe-
cifically, TRAIL-resistant LNCaP cells can be sensitized by
chemotherapeutic drugs and irradiation through upregulation of
death receptors DR4 and/or DR5 [31,32]. Similarly, our in vitro
study has demonstrated the upregulation of DR4 and DR5 in PC-3
and LNCaP cells by resveratrol [14,15]. Interestingly, resveratrol
sensitized TRAIL-resistant LNCaP xenografts by inhibiting tumor
cell proliferation and inducing apoptosis which were correlated with
induction of death receptors DR4 and DR5. Death receptor (DR4
and/or DR5) regulation has been shown to be under the control of
transcription factor NFkB, SP1 and p53 [64,65,66]. Inducible
silencing of DR5 in vivo promoted bioluminescent colon tumor
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5-fluorouracil [67]. These finding suggest that upregulation of DR4
and DR5 by resveratrol may be one of the mechanisms by which
resveratrol enhances the therapeutic potential of TRAIL.
In a recent report, resveratrol and resveratrol-49-O-sulfate were
able to inhibit the activity of COX-1 and -2, at concentrations that
have been shown to be achievable in human plasma [68]. These
data indicate that resveratrol and its 49-O-sulfate metabolite may
mediate or contribute to the health benefits attributed previously
only to resveratrol. Resveratrol and its 49-O-sulfate metabolite
inhibit COX-1 and COX-2 with similar efficacy, and X-ray
structural and computational studies indicate these compounds
bind in the cyclooxygenase sites of the enzymes. In another study,
resveratrol was identified as a potent, mechanistic-based inhibitor
of COX-1 (but not COX-2) [69]. In the same study, resveratrol
was also found to be an ineffective inhibitor against COX-2.
Several studies, which measured the PGE2 production using this
immunoassay system, have shown that resveratrol is an inhibitor of
both COX-1 and -2 enzymatic activities [70]. Furthermore, it has
been demonstrated that resveratrol binds directly to COX-2 and
that this binding is absolutely required for the inhibition of cancer
cell growth by resveratrol [70]. Therefore, the observation that
resveratrol and its 49-Osulfate metabolite inhibit both COX-1 and
COX-2 enzymes with nearly the same efficacy is of importance
since selective inhibition of either one of the enzymes has shown to
lead to serious side effects such as gastric ulcer, heart attack, and
stroke. Compounds that target both enzymes equipotently instead
might provide beneficial effects without the complications due to
single enzyme inhibition.
In summary, our in vivo experiments have demonstrated that
resveratrol can enhance the therapeutic potential of TRAIL
through multiple mechanisms. It induces death receptors (DR4
and DR5) and cell cycle inhibitor p27
/KIP1, upregulates Bax,
inhibits antiapoptotic Bcl-2 protein and markers of cell prolifer-
ation (PCNA and Ki67), metastasis (MM2 and MMP7) and
angiogenesis (VEGF and VEGF-R2). Furthermore, resveratrol
activates FKHRL1 which may result in regulation of Bim,
TRAIL, p27, and cyclin D1. FOXO transcription factor has
been shown to regulate invasion, metastasis and angiogenesis. All
these events will significantly contribute to the antiproliferative and
antitumor activities of resveratrol. Our studies demonstrate strong
clinical potential because resveratrol, either alone or in combina-
tion with TRAIL, can be used for the management of prostate
cancer.
Methods
Ethics statement
All experiments involving animals were approved by the
Institutional Animal Care and Use Committee (IACUC) at the
University of Texas Health Science Center at Tyler, protocol
#373.
Reagents
Antibodies against Bcl-2, Bax, TRAIL-R1/DR4, TRAIL-R2/
DR5, CD31, VEGF, VEGFR2 and b-actin were purchased from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Antibodies
against p27
/KIP1, phospho-FKHRL1, cyclin D1, MMP-2 and
MMP-9 were purchased from Cell Signaling Technology, Inc.
(Danvers, MA). Enhanced chemiluminescence (ECL) Western blot
detection reagents were from Amersham Life Sciences Inc.
(Arlington Heights, IL). Terminal Deoxynucleotidyl Transferase
Biotin-dUTP Nick End Labeling (TUNEL) assay kit was
purchased from EMD Biosciences (San Diego, CA). TRAIL was
purified as described elsewhere [71]. Resveratrol was purchased
from LKT Laboratories, Inc. (St. Paul, MN).
Western Blot Analysis
Western blots were performed as we described earlier [42]. In
brief, tumors were lysed in RIPA buffer containing 1 X protease
inhibitor cocktail, and protein concentrations were determined
using the Bradford assay (Bio-Rad, Philadelphia, PA). Proteins
were separated by 12.5% SDS/PAGE and transferred to
Immobilon membranes (Millipore, Bedford, MA) using semidry
method. After blotting in 5% nonfat dry milk in TBS, the
membranes were incubated with primary antibodies at 1:1,000
dilution in TBS overnight at 4uC, and then secondary antibodies
conjugated with horseradish peroxidase at 1:5,000 dilution in
TBS-Tween 20 for 1 hour at room temperature. Membranes were
washed three times with TBS-Tween 20, and protein bands were
visualized on X-ray film using an enhanced chemiluminescence
system.
Xenograft Assays in Nude Mice
Athymic nude mice (Balb c nu/nu, 4–6 weeks old) were
purchased from the National Cancer Institute (Frederick, MD).
PC-3 cells (2610
6 cells as a 50% suspension in matrigel, Becton
Dickinson, Bedford, MA) in a final volume of 0.1 ml were injected
subcutaneously at right flank of Balb c nude mice. When the
average tumor volume reached about 100 mm
3, mice were
randomized into four groups of 10 mice/group, and the following
treatment protocol was implemented: Group 1, vehicle control
(0.1 ml normal saline) administered through gavage, three times/
week (Monday, Wednesday and Friday) beginning when tumor
volume reached about 100 mm
3; Group 2, TRAIL (15 mg/kg)
administered through i.v. on day 1, 7, 14, and 21; Group 3,
resveratrol (30 mg/kg, in 0.1 ml normal saline) administered
through gavage, three times/week (Monday, Wednesday and
Friday); Group 4, resveratrol and TRAIL, resveratrol administered
through gavage, and TRAIL administered through i.v. Mice were
housed under pathogen-free conditions and maintained on a 12 h
light/12 h dark cycle, with food and water supplied ad libitum.
Immunohistochemistry
Immunohistochemistry was performed as described earlier (28,
29). In brief, tumor tissues were collected, excised and fixed with
10% formalin, embedded in paraffin and sectioned. Tissue
sections were stained with primary antibodies against Bax, Bcl-2,
DR4, DR5, Ki-67, PCNA, p27
/Kip1, phospho-FKHRL1, CD31,
VEGF, VEGFR2, MMP-2 and MMP-9 or TUNEL reaction
mixture. For immunohistochemistry, sections were fixed, air-dried,
and incubated with various primary antibodies at room temper-
ature for 4 h. Subsequently, slides were washed three times in PBS
and incubated with secondary antibody at room temperature for
1 h. Finally, alkaline phosphatase or hydrogen peroxide polymer-
AEC chromagen substrate kits were used as per manufacturer’s
instructions (Lab Vision Corporation). After washing with PBS,
Vectashield (Vector Laboratories) mounting medium was applied
and sections were coverslipped and imaged.
Electrophoretic Mobility Shift Assay
Nuclear extracts from tumor samples were incubated with
32P-
labeled FOXO consensus sequence in a buffer containing 20 mM
HEPES (pH 7.9), 20% glycerol, 100 mM KCl, 0.2 mM EDTA,
0.5 mM phenylmethylsulfonyl fluoride, and 0.5 mM DTT for
30 min at 25uC. Protein-DNA complexes were resolved on a high
ionic strength 5% polyacrylamide gel containing 0.5 x Tris-borate
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45 nM boric acid, and 2 mM EDTA]. Dried gels were subjected
to autoradiography.
Statistical Analysis
The mean and SD were calculated for each experimental
group. Differences between groups were analyzed by one or two
way ANOVA using PRISM statistical analysis software (GrafPad
Software, Inc., San Diego, CA). The non-parametric Mann-
Whitney U test was performed to assess the difference of tumor
volume between control and treatment groups. Significant
differences among groups were calculated at P,0.05.
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